Overview
Topos Bio builds an AI-enabled drug discovery platform that targets intrinsically disordered proteins (IDPs), which are linked to diseases like Alzheimer's, Parkinson's, and cancer. Its core product, Topos-1, generates conformational ensembles of IDPs and finds transient binding opportunities for small molecules, peptides, and degraders, with a wet-lab loop that validates and refines the AI models. The company differs from others by modeling protein dynamics instead of fixed structures and by combining physics, AI, and neuroscience, plus collaborating with Gladstone Institutes to modulate alpha-synuclein. Its goal is to rationally design therapeutics against IDPs—from neuroscience into oncology and metabolic diseases—through partnerships and a growing discovery pipeline.
Work here?Claim your company
Simplify's take
What believers are saying
- September 2026 Topos-2 beat BioEmu, AlphaFold-2, and Boltz-2 on PeptoneBench.
- June 2026 TuneLab membership broadens data access and improves model training without full pharma dependence.
- November 2026 CDD Vault adoption signals operational maturity and tighter IP control.
What critics are saying
- Topos still has one seed round; drug discovery timelines can outrun 2026 cash runway.
- Internal benchmark wins do not equal clinical candidates; wet-lab validation remains the bottleneck.
- If Topos-Bind fails on alpha-synuclein, the IDP platform loses its first credible indication.
What makes Topos Bio unique
- Topos-2 and Topos-Bind target intrinsically disordered proteins with ensemble-first modeling, unlike AlphaFold.
- June 2026 Lilly TuneLab access gives Topos proprietary ADMET data and federated learning leverage.
- Gladstone and Dalriada collaborations validate Topos across alpha-synuclein and proteomics workflows.
Help us improve and share your feedback! Did you find this helpful?